SCHEMBL19393993

SCHEMBL19393993

CC(C)C(C(=O)OCc1ccccc1)N(C)CCc1ccc(NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.44
▸ TDP1 Q9NUW8 3/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ DRD2 P14416 1/20 0.43
▸ GLS O94925 1/20 0.43
▸ ADAMTS4 O75173 1/20 0.42
▸ SYK P43405 1/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ NPY5R Q15761 1/20 0.41
▸ LTA4H P09960 1/20 0.41
▸ CYP17A1 P05093 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ NAMPT P43490 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NTSR1 P30989 1/20 0.39
▸ TOP2A P11388 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16202118 1.00 MAPT (0.44) MAPTTDP1MAPK1DRD2GLS
SCHEMBL21963468 0.87 CYP17A1 (0.45) DRD2GLSADAMTS4CYP17A1PPARA
SCHEMBL19393982 0.86 CYP17A1 (0.46) DRD2GLSADAMTS4NPY5RCYP17A1
SCHEMBL16197807 0.86 CYP17A1 (0.46) DRD2GLSADAMTS4NPY5RCYP17A1
SCHEMBL18489859 0.84 KDM4E (0.44) MAPTKDM4ENPY5RPOLB
SCHEMBL18522836 0.84 KDM4E (0.44) MAPTKDM4ENPY5RPOLB
SCHEMBL18522844 0.84 NPC1 (0.46) MAPTMAPK1DRD2ADAMTS4KDM4E
SCHEMBL20748783 0.83 PAX8 (0.42) MAPTSYKKDM4EPOLB
SCHEMBL18489870 0.83 PAX8 (0.42) MAPTSYKKDM4EPOLB
SCHEMBL21699515 0.82 SYK (0.51) MAPTTDP1MAPK1SYKPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607996-B1 ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER PF MEDICAMENT (FR) 2023-01-04 — — EP disclosed
EP-3388427-B1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS PF MEDICAMENT (FR) 2022-01-19 — — EP disclosed
EP-3607996-A1 ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2020-02-12 — — EP disclosed
EP-3498301-A1 KIT COMPRISING IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER PIERRE FABRE MEDICAMENT (FR) 2019-06-19 — — EP disclosed
EP-3134124-B1 IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER PF MEDICAMENT (FR) 2019-02-20 — — EP disclosed
EP-2989088-B1 DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS PF MEDICAMENT (FR) 2017-09-27 — — EP disclosed
Send feedback